The Repurposing Drugs in Oncology (ReDO) Project

The Repurposing Drugs in Oncology (ReDO) Project seeks to repurpose well-known and well-characterised non-cancer drugs for new uses in oncology. The rationale for this project is presented, examining current issues in oncological drug development, challenges for health systems, and existing and future patient needs. In addition to discussing the advantages of repurposing, the paper also outlines some of the characteristics used in the selection of drug candidates by this project. Challenges in moving candidate drugs into clinical trial and subsequent practice are also discussed.

[1]  Robert Axelrod,et al.  Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. , 2008, Translational oncology.

[2]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[3]  Amir Abdollahi,et al.  Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[5]  H. Kubo,et al.  Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Ayfer Ali,et al.  The Major Role of Clinicians in the Discovery of Off‐Label Drug Therapies , 2006, Pharmacotherapy.

[7]  Saroj Niraula,et al.  Metformin in cancer: translational challenges. , 2012, Journal of molecular endocrinology.

[8]  F. Vera-Badillo,et al.  Benefit and Harms of New Anti-Cancer Drugs , 2013, Current Oncology Reports.

[9]  R. Epstein.  The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe , 2013, Front. Oncol..

[10]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[11]  T. Fojo,et al.  Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? , 2010, Clinical Cancer Research.

[12]  A. Plowright,et al.  What is the most important approach in current drug discovery: doing the right things or doing things right? , 2012, Drug discovery today.

[13]  O. Dekkers,et al.  Use of Aspirin postdiagnosis improves survival for colon cancer patients , 2012, British Journal of Cancer.

[14]  F. Berrino,et al.  Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects , 2013, Oncogene.

[15]  Janet Woodcock,et al.  Expediting drug development--the FDA's new "breakthrough therapy" designation. , 2013, The New England journal of medicine.

[16]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[17]  J. DiMasi,et al.  Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009 , 2011, Clinical pharmacology and therapeutics.

[18]  O. Scharovsky,et al.  Metronomic chemotherapy: changing the paradigm that more is better , 2009, Current oncology.

[19]  Nicolas André,et al.  Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.

[20]  N. André,et al.  Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. , 2011, Translational oncology.

[21]  L. Xing,et al.  Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials , 2013, PLoS ONE.

[22]  A. Jemal,et al.  Global Patterns of Cancer Incidence and Mortality Rates and Trends , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[23]  H. Ghofrani,et al.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.

[24]  Lili Wang,et al.  Molecular‐targeted agents combination therapy for cancer: Developments and potentials , 2014, International journal of cancer.

[25]  Thomas Bachelot,et al.  Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). , 2014, The Lancet. Oncology.

[26]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[27]  N. Leighl,et al.  Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Kareva.  What can ecology teach us about cancer? , 2011, Translational oncology.

[29]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[30]  P. Vineis,et al.  Global cancer patterns: causes and prevention , 2014, The Lancet.

[31]  Jun O. Liu,et al.  Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[33]  S. Deva,et al.  Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. , 2012, The Cochrane database of systematic reviews.

[34]  Francisco Cervantes,et al.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. , 2013, Blood.

[35]  P. Bruzzi,et al.  Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  E. Gorak,et al.  Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. , 2013, The oncologist.

[37]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[38]  Min Huang,et al.  Molecularly targeted cancer therapy: some lessons from the past decade. , 2014, Trends in pharmacological sciences.

[39]  Derek LeRoith,et al.  Diabetes, cancer, and metformin: connections of metabolism and cell proliferation , 2011, Annals of the New York Academy of Sciences.

[40]  Susan Halabi,et al.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.

[41]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  L. Zitvogel,et al.  Trial Watch , 2014, Oncoimmunology.

[43]  Tiffany Shao,et al.  The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Kelvin K. W. Chan,et al.  Low-dose metronomic chemotherapy: a systematic literature analysis. , 2013, European journal of cancer.

[45]  A. Ring,et al.  Aspirin as a treatment for cancer. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[46]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[47]  V. Bobek,et al.  Cimetidine: an anticancer drug? , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[48]  S. Crawford.  Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy , 2013, Front. Pharmacol..

[49]  L. Leibovici,et al.  The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review , 2013, PloS one.

[50]  J. Drevs,et al.  Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. , 2004, Anticancer research.

[51]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[52]  P. Hahnfeldt,et al.  Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.

[53]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[54]  K. Lisy.  Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. , 2013, Clinical journal of oncology nursing.

[55]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[56]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.